Medicenna Therapeutics (MDNA) News Today → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free MDNA Stock Alerts C$2.85 +0.53 (+22.84%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28, 2024 | investing.comMedicenna (MDNA) Earnings Dates & ReportsMay 22, 2024 | finance.yahoo.comMedicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation ForumMay 13, 2024 | finance.yahoo.comMedicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program CommitteeMay 13, 2024 | finance.yahoo.comMedicenna Provides Update on its Presentations at the 2024 ASCO Annual MeetingMay 7, 2024 | seekingalpha.comNew Buy, Medicenna: Superkine Platform In OncologyApril 26, 2024 | ca.finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - MDNAApril 26, 2024 | finance.yahoo.comMedicenna Therapeutics Announces CA$20 Million Investment from RA Capital ManagementApril 9, 2024 | finance.yahoo.comMedicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)April 9, 2024 | finance.yahoo.comMedicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)March 27, 2024 | theglobeandmail.comMedicenna Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (MDNA)March 6, 2024 | finance.yahoo.comMedicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual MeetingFebruary 13, 2024 | finance.yahoo.comMedicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsJanuary 9, 2024 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabJanuary 9, 2024 | finance.yahoo.comMedicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabNovember 20, 2023 | finance.yahoo.comAll You Need to Know About Medicenna Therapeutics Corp. (MDNAF) Rating Upgrade to BuyNovember 14, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational HighlightsNovember 9, 2023 | finance.yahoo.comMedicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingOctober 24, 2023 | tmcnet.comMedicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)October 24, 2023 | finance.yahoo.comMedicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)October 10, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerOctober 5, 2023 | nasdaq.comMedicenna Therapeutics (MDNA) Price Target Increased by 34.63% to 3.93October 3, 2023 | finance.yahoo.comMedicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and ImmunotherapySeptember 29, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Announces Results of Annual and Special Meeting of ShareholdersSeptember 28, 2023 | finance.yahoo.comMedicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and ImmunotherapySeptember 26, 2023 | finance.yahoo.comIs Medicenna Therapeutics (TSE:MDNA) In A Good Position To Invest In Growth?September 6, 2023 | finance.yahoo.comMedicenna to Participate at The H.C. Wainwright 25th Annual Global Investment ConferenceAugust 28, 2023 | msn.comMedicenna Therapeutics gets new CFOAugust 28, 2023 | finance.yahoo.comMedicenna Announces the Appointment of Jeff Caravella as Chief Financial OfficerAugust 24, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp up on Wednesday (MDNA)August 13, 2023 | markets.businessinsider.comBloom Burton Thinks Medicenna Therapeutics Corp’s Stock is Going to RecoverAugust 9, 2023 | finance.yahoo.comMedicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY StudyAugust 2, 2023 | msn.comMedicenna Therapeutics (MDNA) Price Target Increased by 5.55% to 3.54June 28, 2023 | benzinga.comHC Wainwright & Co. Reiterates Buy on Medicenna Therapeutics, Maintains $2.5 Price TargetJune 28, 2023 | markets.businessinsider.comH.C. Wainwright Maintains Their Buy Rating on Medicenna Therapeutics Corp (MDNA)April 19, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp up on Tuesday (MDNA)April 18, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp up on Monday (MDNA)April 8, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp down on Thursday (MDNA)February 8, 2023 | finance.yahoo.comMedicenna Therapeutics Corp. (NASDAQ:MDNA) Q3 2023 Earnings Call TranscriptFebruary 6, 2023 | benzinga.comMedicenna Therapeutics Earnings PreviewFebruary 6, 2023 | benzinga.comEarnings Preview For Medicenna TherapeuticsJanuary 26, 2023 | finance.yahoo.comMedicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023November 10, 2022 | finance.yahoo.comMedicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual MeetingNovember 8, 2022 | finance.yahoo.comMedicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth PlansNovember 3, 2022 | msn.comEarnings Outlook For Medicenna TherapeuticsOctober 28, 2022 | finance.yahoo.comMedicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementOctober 6, 2022 | finance.yahoo.comMDNA: Confirmed Partial Response in Pancreatic Cancer Patient…October 5, 2022 | finance.yahoo.comMedicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual MeetingSeptember 28, 2022 | finance.yahoo.comMedicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY StudySeptember 13, 2022 | finance.yahoo.comMedicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY TrialSeptember 8, 2022 | finance.yahoo.comMedicenna to Present at Investor and Scientific Conferences in September Get Medicenna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”. You just have to make this simple move before July 30, 2024. MDNA Media Mentions By Week MDNA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDNA News Sentiment▼0.000.76▲Average Medical News Sentiment MDNA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDNA Articles This Week▼10▲MDNA Articles Average Week Get Medicenna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Fennec Pharmaceuticals News Oncolytics Biotech News Sernova News Theratechnologies News ProMIS Neurosciences News Small Pharma News Microbix Biosystems News IBEX Technologies News Covalon Technologies News Aptose Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:MDNA) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
